Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-naïve HIV-1-infected patients over 96 weeks

HIV Clinical Trials

Volumn 10, Issue 6, 2009, Pages 375-384

  Jayaweera, Dushyantha ^a   Dejesus, Edwin ^b   Nguyen, Kim L ^c   Grimm, Kristy ^c   Butcher, David ^c   Seekins, Daniel W ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Adherence; Efavirenz; HIV 1; Quality of life

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; STAVUDINE;

ABNORMAL DREAMING; ADULT; AGED; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLIPIDEMIA; INSOMNIA; LIBIDO DISORDER; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NEUROPATHY; PARESTHESIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SKIN TINGLING; TREATMENT OUTCOME;

ADULT; AGED; BENZOXAZINES; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STAVUDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 76749160374     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1006-375     Document Type: Article

References (22)

1. Lucas GM, Wu AW, Cheever LW. Adherence to antiretroviral therapy: an update of current concepts. Curr HIV/AIDS Rep. 2004;1(4):172-180.
2. Roge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 2004;5(5):344-351.
3. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808-816.
4. Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21(3):271-281.
5. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials. 2008;9(3):164-176.
6. Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther. 2004;2(5): 671-684.
7. Riddler SA, Haubrich R, DiRienzo G, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-2106.
8. DeJesus E, Cohen C, Sax P. Improvement in quality of life (QoL) with once daily didanosine EC (DDI-EC), lamivudine (3TC) and efavirenz (EFV): 24 week interim results from the DART I trial. Presented at: Annual Meeting of the Infectious Disease Society of America; October 9-12; 2003; San Diego, CA.
9. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6(6):481-493.
10. Badia X, Podzamczer D, Garcia M, Lopez-Lavid CC, Consiglio E. A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. Medical Outcomes Study HIV Health Survey. AIDS. 1999;13(13):1727-1735.
11. Felizarta F, DeJesus E, Jayaweera D, et al. High adherence with once-daily efavirenz-based regimens: 96 week results from the Daily Antiretroviral Therapy I & II (DART I & II) trials. Proceedings of the National Institute of Mental Health/ International Association of Physicians in AIDS Care International Conference on HIV Treatment Adherence; March 8-10, 2006; Jersey City, NJ, USA. Abstract 228.
12. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
13. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37(8):1112-1118.
14. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002;29(suppl 1):S2-10.
15. Battaglioli-DeNero AM. Strategies for improving patient adherence to therapy and long-term patient outcomes. J Assoc Nurses AIDS Care. 2007;18(1 suppl):S17-S22.
16. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1):158-163.
17. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effects of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI-or PI-treated patients. HIV Clin Trials. 2007;8(5):282-292.
18. Rosenblum M, Deeks SG, Van Der Laan MJ, Bangsberg DR. The risk of virologic failure decreases with duration of continuous viral suppression for adherence levels above 50%. Presented at: the 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract 583.
19. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169-177.
20. Berenguer J, Gonzalez J, Ribera E, et al. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis. 2008;47(8):1083-1092.
21. Santos J, Palacios R, Lozano F, et al. Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naïve patients: 3-year follow-up. AIDS Res Hum Retroviruses. 2008;24(1):24-26.
22. Sanchez-Conde M, Palacios R, Sanz J, et al. efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: the ELADI study. AIDS Res Hum Retroviruses. 2007;23(10):1237-1241.